R. A'Hern

发表

Does chemotherapy improve survival in advanced breast cancer? A statistical overview.

S. Ebbs, R. A’Hern, M. Baum, 1988, British Journal of Cancer.

Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma

J. Thomas, R. A'hern, T. M. Hughes, 2000, The British journal of surgery.

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.

S. Ebbs, I. Smith, R. A’Hern, 1993, British Journal of Cancer.

Childhood T-cell lymphoblastic lymphoma--does early resolution of mediastinal mass predict for final outcome? The United Kingdom Children's Cancer Study Group (UKCCSG).

C. R. Pinkerton, R. A’Hern, S. Shepherd, 1995, British Journal of Cancer.

Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).

R. A’Hern, J. Hardy, P. Ling, 1995, British Journal of Cancer.

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.

M. Gore, R. A’Hern, P. Riches, 1998, British Journal of Cancer.

A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma

M. Gore, K. Harrington, R. A’Hern, 2004, British Journal of Cancer.

Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer.

M. Dowsett, A. Harris, R. A’Hern, 1995, British Journal of Cancer.